Amantadine Shortage in 2026: A Provider and Prescriber Update

The ongoing shortage of Amantadine hydrochloride continues to affect clinical workflows and patient outcomes heading into 2026. This article provides a comprehensive update for neurologists, primary care physicians, psychiatrists, and other prescribers managing patients on Amantadine — including supply chain details, formulary implications, clinical alternatives, and practical strategies for patient management.

For a companion resource on helping patients locate available supply, see our provider's guide to helping patients find Amantadine in stock.

Supply Chain Status

Manufacturer Discontinuations

The primary driver of the current shortage is the exit of two major generic manufacturers from the Amantadine market:

• Strides Pharma — discontinued Amantadine HCl 100 mg capsules (business decision)
• Teva Pharmaceuticals — discontinued Amantadine HCl 100 mg capsules (business decision)

Neither discontinuation was related to safety signals, GMP violations, or FDA enforcement actions. These represent market exits driven by the low-margin economics of mature generic products.

Current Availability by Formulation

The shortage does not affect all Amantadine formulations equally:

• 100 mg capsules (IR, generic): Most affected. Intermittent availability at retail pharmacies. Regional variation is significant.
• 100 mg tablets (IR, generic): Better availability. Some patients can be transitioned to tablets with a new prescription.
• Oral solution (50 mg/5 mL, generic): Generally available. Useful for dose titration or patients who have difficulty swallowing.
• Gocovri (ER capsules, 68.5 mg/137 mg): Available through specialty pharmacy channels. FDA-approved specifically for levodopa-induced dyskinesia (LID) and OFF episodes in PD. Significantly higher cost; typically requires prior authorization.
• Osmolex ER (ER tablets, 129 mg/193 mg/258 mg): Available. Approved for Parkinson's disease and drug-induced EPS. Also higher cost with frequent PA requirements.

FDA and ASHP Monitoring

Both the FDA Drug Shortage Database and the ASHP Drug Shortage Resource Center are actively tracking Amantadine. The FDA continues to engage with remaining manufacturers regarding production capacity but does not have authority to mandate manufacturing.

Clinical Impact Assessment

Patient Populations Most Affected

1. Parkinson's disease patients on Amantadine for dyskinesia management — Amantadine (particularly in its ER formulation as Gocovri) remains the only FDA-approved oral agent for levodopa-induced dyskinesia. Loss of access can lead to significant motor deterioration and reduced quality of life.
2. Patients receiving antipsychotics with drug-induced EPS — Amantadine is frequently used as a first-line agent for extrapyramidal symptoms. Disruption requires rapid substitution to prevent patient distress and potential non-adherence to antipsychotic therapy.
3. Patients using Amantadine off-label for MS fatigue or TBI recovery — While evidence is mixed, many patients report meaningful subjective benefit. Discontinuation may lead to functional decline.

Critical Safety Consideration: Withdrawal Risk

Providers should proactively counsel patients about the risks of abrupt discontinuation. Amantadine withdrawal can precipitate:

• Neuroleptic malignant syndrome (NMS) — including hyperthermia, muscular rigidity, altered consciousness, and autonomic instability
• Parkinsonism-hyperpyrexia syndrome — particularly in PD patients
• Rebound worsening of underlying symptoms

If a patient's supply is running low with no resupply available, a gradual taper over 1-2 weeks is recommended. Do not allow patients to run out without a management plan.

Clinical Alternatives by Indication

For Levodopa-Induced Dyskinesia

Amantadine holds a unique position as the only approved oral antidyskinetic agent. In its absence, consider:

• Levodopa dose fractionation: Reduce individual Levodopa/Carbidopa doses while increasing frequency to smooth plasma levels and reduce peak-dose dyskinesia.
• Extended-release Levodopa formulations (Rytary, Dhivy): May provide more consistent plasma levels with less pulsatile stimulation.
• Gocovri ER: If generic IR is unavailable, the brand ER formulation may be accessible through specialty pharmacy. The manufacturer's Gocovri Onboard program offers copay assistance.
• Safinamide (Xadago): While primarily a MAO-B inhibitor, its glutamate-modulating properties may provide modest antidyskinetic benefit. Evidence is limited for this specific indication.
• Deep brain stimulation (DBS) referral: For patients with medically refractory dyskinesia, the shortage may accelerate surgical referral timelines.

For Parkinson's Disease (Monotherapy or Adjunct)

• Dopamine agonists: Ropinirole (Requip), Pramipexole (Mirapex), or Rotigotine (Neupro patch) — widely available generics (except Rotigotine). Monitor for impulse control disorders.
• MAO-B inhibitors: Selegiline, Rasagiline (Azilect), or Safinamide (Xadago) — particularly for early-stage PD or as Levodopa adjuncts.
• COMT inhibitors: Entacapone (Comtan) or Opicapone (Ongentys) — extend Levodopa duration; useful for patients with wearing-off phenomena.
• Anticholinergics: Trihexyphenidyl or Benztropine — primarily for tremor-predominant PD; avoid in elderly patients due to cognitive effects.

For Drug-Induced Extrapyramidal Symptoms

• Benztropine (Cogentin): First-line alternative. Available as generic oral and injectable. Caution in elderly and cognitively impaired patients.
• Trihexyphenidyl: Alternative anticholinergic. Similar efficacy and side effect profile.
• Diphenhydramine: Useful for acute dystonic reactions. Limited role in chronic EPS management.
• Dose reduction or switch of offending antipsychotic: When clinically appropriate, consider switching to a second-generation antipsychotic with lower EPS liability (e.g., Quetiapine, Clozapine).

Formulary and Insurance Considerations

The shortage creates several practical challenges for prior authorization and formulary navigation:

• PA for brand alternatives: Most payers require documentation of generic unavailability before approving Gocovri or Osmolex ER. Consider documenting pharmacy stock-out confirmations in the medical record.
• Step therapy overrides: If a payer's step therapy requires generic Amantadine before approving a brand alternative, a shortage exception request citing manufacturer discontinuations may be warranted.
• Specialty pharmacy referral: Gocovri is distributed through specialty pharmacy channels. Initiation can take 1-2 weeks; plan accordingly.

Patient Communication Strategies

Proactive communication can reduce patient anxiety and prevent dangerous self-management decisions:

1. Inform patients early: If you're aware of supply issues, alert patients at their next visit rather than waiting for a crisis at the pharmacy.
2. Provide a contingency plan: Give patients a written plan — e.g., "If your pharmacy can't fill Amantadine, call our office. Do not stop taking it without our guidance."
3. Direct patients to resources: MedFinder for Providers offers tools to help locate pharmacy stock. You can also direct patients to our patient-facing shortage update for educational context.

Documentation Recommendations

In the context of drug shortages, thorough documentation protects both patients and providers:

• Document the clinical rationale for Amantadine use in the patient's chart
• Record pharmacy stock-out reports and dates
• Document clinical reasoning for any medication switches, including risks discussed with the patient
• Note any taper plans if Amantadine must be discontinued

Resources for Providers

• MedFinder for Providers — pharmacy stock search and patient guidance tools
• FDA Drug Shortage Database — official shortage tracking
• ASHP Drug Shortage Resource Center — clinical management recommendations
• Gocovri Onboard Program — copay and patient assistance for the ER brand

For additional guidance on helping patients locate supply, see our provider's guide to finding Amantadine in stock.